Click here for slides on this topic


Basal insulin

A type of long-acting insulin that works to control insulin levels over a 24-hour period.


The following content matched the glossary term: Basal insulin

NDEI.org Expert Commentary Silvio E. Inzucchi MD on Type 2 Diabetes Treatment Recommendations

Top

EXPERT COMMENTARY New Silvio E. Inzucchi, MD, on Phentermine Plus Topiramate for Weight Loss in Type 2 Diabetes   Silvio E. Inzucchi, MD  Weight loss remains a great challenge for our patients, especially those with type 2 diabetes. While lifestyle

AACE 2015 guidelines Glycemic Control Algorithm

Top

AACE’s glycemic control algorithm outlines pharmacologic treatment options for diabetes from the 2015 AACE guidelines 

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

ADA 2016 Type 1 Diabetes Pharmacologic Therapy

Top

Type 1 diabetes treatment options from the 2016 ADA guidelines

ADA 2016 Insulin & Glucose Monitoring

Top

Recommendations for insulin and glucose monitoring in diabetes (SMBG) from the 2016 ADA guidelines

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

1 2 3 4 Next 

Slide Library Results

Search Results for: Basal insulin Slides Found: 55
ORIGIN Trial: Design
ORIGIN Trial: Baseline Characteristics (1 of 2)
ORIGIN Trial: Baseline Characteristics (2 of 2)
ORIGIN Trial: Results
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
EASIE Trial: Design
EASIE Trial: Study and Enrollment Profile
EASIE Trial: Efficacy Population Primary Outcome at Week 24—Change in A1C from Baseline
EASIE Trial: Efficacy Population A1C <7.0% and <6.5% Week 24
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
ORIGIN: Design
Inpatient Glycemic Control: Is There an Optimal Insulin Strategy?
Basal Plus Trial: Design and Randomization
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Study Protocol and Meals
ADA/Endocrine Society: Strategies for Preventing Hypoglycemia (2 of 2)
Efficacy of Twice-Daily Exenatide Added to Basal Insulin for A1C Reduction: Design
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo : A1C Reduction at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Target A1C Levels at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Body Weight 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Hypoglycemia at 30 Wks
Twice-Daily Exenatide Vs Placebo Added to Basal Insulin: Adverse Events
Type 2 Diabetes Treatment Intensification Micro- Macrovascular | NDEI
Type 2 Diabetes Treatment Intensification Acute MI | NDEI
Type 2 Diabetes Treatment Intensification Albuminuria | NDEI
Type 2 Diabetes Treatment Intensification eGFR Kidney | NDEI
IDF 2012 Type 2 Diabetes Guidelines Insulin Therapy | NDEI
Basal Insulin Glycemic Control A1C Type 2 Diabetes | NDEI
ADA Type 1 Diabetes Guidelines Physical Activity | NDEI Diabetes Slides
Inpatient Outpatient Management ADA Type 1 Diabetes Guidelines | NDEI
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
ADA EASD Position Statement Insulin Use in Type 2 Diabetes | NDEI
Combination GLP-1 RA & Basal Insulin Treatment Type 2 Diabetes | NDEI
Hypoglycemia & Weight After Treatment With GLP-1 RA + Basal Insulin | NDEI
AACE 2015 Guidelines Treating Gestational Diabetes GDM PPT | NDEI
Insulin Glargine Neutral on CV Outcomes & Cancer Diabetes ORIGIN | NDEI
Neutral Omega-3 Effect on CV Outcomes in ORIGIN Diabetes | NDEI
Insulin Glargine A1C Reduction Type 2 Diabetes PPT | NDEI
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
ORIGINALE No Increase in CV Events or Cancer with Insulin Glargine Diabetes | NDEI
ORIGINALE No Effect of Omega-3 Fatty Acids on CV Outcomes | NDEI
ORIGINALE A1C Reduction With Insulin Glargine Type 2 Diabetes | NDEI